Another deal! Hengrui Pharma partners with BMS in strategic collaboration with a potential transaction value of $15.2 billion | Flash Report

① Hengrui and BMS have signed an agreement to jointly advance 13 early-stage projects covering oncology, hematology, and immunology; ② BMS will pay an upfront fee of $600 million and an anniversary payment of $350 million, with milestone payments reaching approximately $15.2 billion. Hengrui is also entitled to receive sales royalties; ③ This represents a two-way licensing collaboration, with Hengrui obtaining the rights to four of BMS's immunology projects in China. The agreement is expected to close in the third quarter of 2026.

cls.cn14:49

Little K Morning Report | Tencent Co-invests in Step's $2.5 Billion Financing; OpenAI Invests Over $4 Billion to Establish New Division

① Investor Michael Burry warned that the Nasdaq 100 Index may experience a significant decline; ② Guangzhou: Supporting the research and development of potential blockbuster smart hardware products such as AI glasses; ③ BeiGene: Net profit for the first quarter was 1.608 billion yuan.

cls.cn07:58

Why did last year's performance decline, how to confirm revenue, and will agency sales be scaled back? Guizhou Maotai responds to investor concerns | Earnings Meeting Coverage

① Last year, Maotai's performance declined for the first time due to an active strategic contraction. In the first quarter of this year, net profit growth lagged behind revenue growth, caused by price reductions of high-end liquor and structural adjustments. ② Regarding the consignment sales model, Maotai will comprehensively coordinate and dynamically adjust product distribution to maintain a stable and orderly market. ③ Maotai emphasized that its financial reports are true, accurate, and complete. Dividends and buybacks will be strictly executed according to plan, and no exclusive purchase channels for shareholders will be established.

cls.cnMay 11 21:27

STAR Market Daily: SMIC's $40.6 billion acquisition approved; MicroSpace STAR Market IPO application accepted.

①South Asia New Material plans to raise no more than 900 million yuan for its AI computing power high-end high-frequency and high-speed copper clad laminate project; ②Guoyi Quantum's STAR Market IPO has been approved; ③Tebao Bio plans to repurchase shares worth between 300 million yuan and 500 million yuan; ④BeiGene reported a net profit of 1.608 billion yuan in the first quarter, reversing a year-on-year loss to profitability.

cls.cnMay 11 21:07

SK Hynix pre-IPO shareholders hold 5 million shares! A 27-billion-yuan memory chip concept stock issues an unusual movement announcement | Post-market announcements highlights

Beijing-Shanghai High-Speed Railway: The published ticket prices for some EMU trains on the Beijing-Shanghai high-speed line and the Hefei-Bengbu high-speed line will increase by 20%.

cls.cnMay 11 20:10

Trends, Group Mentality, and Frenzy – A Guide to the 'Main Theme' Investment Approach in China's A-Share Market

The strategy research report system of SDIC Securities elaborates on the methodology for identifying key themes in the A-share market, proposing four major tools: macro narratives, industry trends, incremental capital, and style rotation. It emphasizes focusing on one or two tools while avoiding mixing them. From the perspective of incremental capital, 'all trends lead to抱团 (concentration),' with excess returns, valuation divergence, and incremental capital peaking sequentially serving as sell signals. Style rotation requires cross-verification of trading signals and logical signals.

wallstreetcnMay 10 19:45